改善轻度认知障碍的老年人认知能力的多组件干预:试点随机对照试验
Kim-Wan Daniel Young1, Chi-Yui Timothy Kwok2, Yat-Nam Petrus Ng3
1Department of Social and Behavioral Sciences, City University of Hong Kong, Hong Kong, China.
Journal of gerontological social work
|April 9, 2024
概括
这项研究发现,16次多元组件干预是可行的,并且有效地改善了轻度认知障碍 (MCI) 的老年人认知能力. 建议进行进一步的大规模试验.
科学领域:
- 老年学是一门学科.
- 神经科学是一个神经科学.
- 公共卫生 公共卫生
背景情况:
- 轻度认知障碍 (MCI) 影响着老年人口的很大一部分.
- 早期干预对于可能减缓认知衰退至关重要.
- 生活方式因素和认知训练在管理MCI方面表现有前途.
研究的目的:
- 评估一种新的16个会话的多组分干预措施的可行性和潜在结果,用于患有MCI的老年人.
- 评估结合健康生活方式,认知技能,太极拳和正念的计划的影响.
主要方法:
- 一项多中心,随机对照试验,涉及57名在香港患有MCI的中国老年人.
- 参与者被分配到对照组或干预组.
- 干预包括16个会议,重点关注生活方式,认知技能,太极拳和正念.
主要成果:
- 多组件干预在目标人群中证明了可行性.
- 初步结果表明,这种干预措施在改善认知能力方面是有效的.
- 这项研究支持该干预措施对MCI患者认知功能的积极影响.
结论:
- 16次多组分干预是MCI老年人的一种可行的方法.
- 这些发现支持整合生活方式,认知,太极拳和正念实践的有效性.
- 需要大规模的随机对照试验来证实这些有希望的结果.
相关概念视频
Cognitive Development During Adulthood
94
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
94
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
122
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
122
Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
Community Based Intervention
41
Community-based interventions in mental health represent a paradigm shift from institution-centered care to treatments embedded within the fabric of local communities. By prioritizing inclusion and leveraging existing societal structures, this approach fosters a supportive environment conducive to addressing mental health challenges while promoting individual dignity and agency.
Foundations of Community Mental Health Programs
Central to the success of community-based interventions is the...
Foundations of Community Mental Health Programs
Central to the success of community-based interventions is the...
41
Working Memory
160
Working memory refers to a combination of components, including short-term memory and attention, that allow an individual to hold information temporarily as we perform cognitive tasks. It is an essential cognitive function that enables the execution of complex tasks such as problem-solving, comprehension, and reasoning. Unlike short-term memory, which simply involves the storage of information for a brief period, working memory involves the active manipulation and processing of this...
160
Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468


